{"protocolSection": {"identificationModule": {"nctId": "NCT06065748", "orgStudyIdInfo": {"id": "CO44657"}, "secondaryIdInfos": [{"id": "2022-502980-39-00", "type": "REGISTRY", "domain": "EU CT Number"}], "organization": {"fullName": "Hoffmann-La Roche", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)", "officialTitle": "A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Hoffmann-La Roche", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant endocrine therapy."}, "conditionsModule": {"conditions": ["Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer"], "keywords": ["oral Selective Estrogen Receptor Degrader (SERD)", "CDK4/6 inhibitor (CDK4/6i)", "ESR1 mutation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 1050, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Giredestrant + Investigator's Choice of CDK4/6i", "type": "EXPERIMENTAL", "description": "Participants in the experimental arm will receive giredestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.", "interventionNames": ["Drug: Giredestrant", "Drug: Abemaciclib", "Drug: Palbociclib", "Drug: Ribociclib", "Drug: LHRH Agonist", "Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)"]}, {"label": "Fulvestrant + Investigator's Choice of CDK4/6i", "type": "ACTIVE_COMPARATOR", "description": "Participants in the control arm will receive fulvestrant plus the investigator's choice of CDK4/6 inhibitor (CDK4/6i): palbociclib, ribociclib, or abemaciclib.", "interventionNames": ["Drug: Fulvestrant", "Drug: Abemaciclib", "Drug: Palbociclib", "Drug: Ribociclib", "Drug: LHRH Agonist", "Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)"]}], "interventions": [{"type": "DRUG", "name": "Giredestrant", "description": "Giredestrant 30 milligrams (mg) orally (PO) once a day (QD) on Days 1-28 of each 28-day cycle until progressive disease (PD) or unacceptable toxicity.", "armGroupLabels": ["Giredestrant + Investigator's Choice of CDK4/6i"], "otherNames": ["RO7197597", "RG6171", "GDC-9545"]}, {"type": "DRUG", "name": "Fulvestrant", "description": "Fulvestrant 500 mg intramuscularly (IM) on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent 28-day cycle until PD or unacceptable toxicity.", "armGroupLabels": ["Fulvestrant + Investigator's Choice of CDK4/6i"]}, {"type": "DRUG", "name": "Abemaciclib", "description": "If chosen by the investigator as the CDK4/6i, participants will receive abemaciclib 150 mg PO twice per day (BID) on Days 1-28 of each 28-day cycle until PD or unacceptable toxicity.", "armGroupLabels": ["Fulvestrant + Investigator's Choice of CDK4/6i", "Giredestrant + Investigator's Choice of CDK4/6i"]}, {"type": "DRUG", "name": "Palbociclib", "description": "If chosen by the investigator as the CDK4/6i, participants will receive palbociclib 125 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.", "armGroupLabels": ["Fulvestrant + Investigator's Choice of CDK4/6i", "Giredestrant + Investigator's Choice of CDK4/6i"]}, {"type": "DRUG", "name": "Ribociclib", "description": "If chosen by the investigator as the CDK4/6i, participants will receive ribociclib 600 mg PO QD on Days 1-21 of each 28-day cycle until PD or unacceptable toxicity.", "armGroupLabels": ["Fulvestrant + Investigator's Choice of CDK4/6i", "Giredestrant + Investigator's Choice of CDK4/6i"]}, {"type": "DRUG", "name": "LHRH Agonist", "description": "Only pre/perimenopausal female participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist locally approved for use in breast cancer on Day 1 of each 28-day treatment cycle.", "armGroupLabels": ["Fulvestrant + Investigator's Choice of CDK4/6i", "Giredestrant + Investigator's Choice of CDK4/6i"]}, {"type": "DIAGNOSTIC_TEST", "name": "FoundationOne Liquid CDx Assay (F1LCDx)", "description": "F1LCDx is a next-generation sequencing (NGS)-based in vitro diagnostic test that detects and analyses genomic alterations in circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. It will be used to determine the eligibility of participants requiring confirmation of ESR1 mutation status (mutation detected \\[ESR1m\\] vs. no mutation detected \\[ESR1nmd\\]).", "armGroupLabels": ["Fulvestrant + Investigator's Choice of CDK4/6i", "Giredestrant + Investigator's Choice of CDK4/6i"], "otherNames": ["F1LCDx"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Locally advanced or metastatic adenocarcinoma of the breast, not amenable to treatment with curative intent\n* Documented estrogen receptor-positive (ER+), HER2-negative (HER2-) tumor assessed locally on the most recent tumor biopsy (or an archived tumor sample if a recent tumor sample is not available for testing)\n* Confirmed ESR1 mutation status (ESR1m versus ESR1nmd) in baseline circulating tumor DNA (ctDNA) through central laboratory testing\n* Resistance to prior adjuvant endocrine therapy (ET), which is defined as having relapsed with prior standard adjuvant ET, on-treatment after \\>/=12 months or off-treatment within 12 months of completion. Prior use of adjuvant CDK4/6i is allowed (if relapse occurred \\>/=12 months since completion).\n* No prior systemic anti-cancer therapy for advanced disease\n* Measurable disease as defined per RECIST v.1.1 or non-measurable (including bone-only) disease\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-1\n* For pre/perimenopausal women and for men: willing to undergo and maintain treatment with approved LHRH agonist therapy (as per local guidelines) for the duration of study treatment\n\nExclusion Criteria:\n\n* Prior systemic therapy (e.g., prior chemotherapy, immunotherapy, or biologic therapy) for locally advanced unresectable or metastatic breast cancer\n* Prior treatment with another SERD (e.g., fulvestrant, oral SERDs) or novel ER-targeting agents\n* Advanced, symptomatic, visceral spread that is at risk of life-threatening complications in the short term\n* Active cardiac disease or history of cardiac dysfunction\n* Clinically significant history of liver disease", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "Reference Study ID Number: CO44657 https://forpatients.roche.com/", "role": "CONTACT", "phone": "888-662-6728 (U.S. Only)", "email": "global-roche-genentech-trials@gene.com"}], "overallOfficials": [{"name": "Clinical Trials", "affiliation": "Hoffmann-La Roche", "role": "STUDY_DIRECTOR"}]}}, "hasResults": false}